Correction: Dynamics of Serial ctDNA as Predictors of Clinical Outcomes

Background

Pancreatic ductal adenocarcinoma (PDAC) is a major contributor to cancer-related mortality, with challenges in treatment response evaluation. Neoadjuvant chemotherapy is increasingly used to improve surgical outcomes, but current biomarkers like CA 19-9 have limitations. The exploration of circulating tumor DNA (ctDNA) is discussed in relation to prognostic assessment in PDAC.

Data Highlights

The correction article does not present numerical data or trial results.

Key Findings

• The correction addresses an attribution error regarding Dr. Zahra Hamedi's affiliation.
• ctDNA dynamics have been identified as potential predictors of clinical outcomes in PDAC.
• Neoadjuvant chemotherapy is being implemented to enhance R0 resection rates in localized PDAC.
• Current methods for evaluating treatment response in PDAC have significant limitations.
• Recent studies indicate that ctDNA presence correlates with clinical outcomes in advanced pancreatic cancer.

Clinical Implications

The correction emphasizes the importance of accurate author attribution in scientific literature.

Conclusion

The correction clarifies authorship.

Related Resources & Content

1. Peshin S, Takrori E, Sahin IH, et al., Front. Oncol., 2026 -- Dynamics of Serial ctDNA as Predictors of Clinical Outcomes in Metastatic and Locally Advanced PDAC: A Systematic Review
2. Journal of Surgical Oncology — Dynamic Prognostic Nutritional Index With Circulating Tumor DNA Predicts Survival in Localized Pancreatic Ductal Adenocarcinoma
3. The Role of Longitudinal ctDNA Assessment via Multiplex MS-ddPCR in Risk Stratification and Monitoring for Rectal Cancer
4. The ASCO Post — Circulating Tumor DNA as a Prognostic Marker in Pancreatic Cancer
5. The ASCO Post — Advancing Clinical Decisions With Circulting Tumor DNA: Insights From Recent Clinical Trials
6. Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline
7. Circulating tumor DNA (ctDNA) as a predictor of progression-free and overall survival in non-resectable pancreatic cancer: a systematic review and meta-analysis